nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—ABCC1—Cyclosporine—psoriasis	0.0649	0.1	CbGbCtD
Mitoxantrone—CYP1B1—Dexamethasone—psoriasis	0.0601	0.0931	CbGbCtD
Mitoxantrone—ABCG2—Mycophenolate mofetil—psoriasis	0.0573	0.0887	CbGbCtD
Mitoxantrone—ABCG2—Hydrocortisone—psoriasis	0.046	0.0712	CbGbCtD
Mitoxantrone—ABCG2—Cyclosporine—psoriasis	0.0434	0.0672	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—psoriasis	0.0343	0.0532	CbGbCtD
Mitoxantrone—ABCG2—Dexamethasone—psoriasis	0.0286	0.0443	CbGbCtD
Mitoxantrone—CYP3A4—Calcitriol—psoriasis	0.0277	0.0429	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—psoriasis	0.023	0.0356	CbGbCtD
Mitoxantrone—CYP3A4—Methoxsalen—psoriasis	0.0215	0.0334	CbGbCtD
Mitoxantrone—ABCB1—Mycophenolate mofetil—psoriasis	0.0207	0.032	CbGbCtD
Mitoxantrone—CYP2E1—Dexamethasone—psoriasis	0.0204	0.0316	CbGbCtD
Mitoxantrone—ABCB1—Betamethasone—psoriasis	0.0177	0.0274	CbGbCtD
Mitoxantrone—ABCB1—Prednisolone—psoriasis	0.0175	0.0271	CbGbCtD
Mitoxantrone—ABCB1—Hydrocortisone—psoriasis	0.0166	0.0257	CbGbCtD
Mitoxantrone—ABCB1—Prednisone—psoriasis	0.0165	0.0256	CbGbCtD
Mitoxantrone—ABCB1—Cyclosporine—psoriasis	0.0157	0.0242	CbGbCtD
Mitoxantrone—CYP3A4—Cholecalciferol—psoriasis	0.0143	0.0221	CbGbCtD
Mitoxantrone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0124	0.0192	CbGbCtD
Mitoxantrone—CYP3A4—Triamcinolone—psoriasis	0.0124	0.0192	CbGbCtD
Mitoxantrone—CYP3A4—Betamethasone—psoriasis	0.0106	0.0164	CbGbCtD
Mitoxantrone—CYP3A4—Prednisolone—psoriasis	0.0105	0.0162	CbGbCtD
Mitoxantrone—ABCB1—Dexamethasone—psoriasis	0.0103	0.016	CbGbCtD
Mitoxantrone—CYP3A4—Hydrocortisone—psoriasis	0.00993	0.0154	CbGbCtD
Mitoxantrone—CYP3A4—Prednisone—psoriasis	0.00989	0.0153	CbGbCtD
Mitoxantrone—CYP3A4—Cyclosporine—psoriasis	0.00938	0.0145	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—psoriasis	0.00828	0.0128	CbGbCtD
Mitoxantrone—CYP3A4—Dexamethasone—psoriasis	0.00618	0.00956	CbGbCtD
Mitoxantrone—CYP1B1—Melatonin metabolism and effects—APOE—psoriasis	0.000431	0.00686	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—SOCS1—psoriasis	0.000425	0.00677	CbGpPWpGaD
Mitoxantrone—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	0.00042	0.258	CbGdCrCtD
Mitoxantrone—BTK—IL-5 Signaling Pathway—STAT3—psoriasis	0.000409	0.00651	CbGpPWpGaD
Mitoxantrone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000406	0.00646	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—HLA-E—psoriasis	0.000401	0.00639	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—NFKB1—psoriasis	0.0004	0.00637	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000388	0.00617	CbGpPWpGaD
Mitoxantrone—CYP1B1—Tryptophan metabolism—CAT—psoriasis	0.000383	0.0061	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.000383	0.0061	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.000378	0.00603	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HLA-E—psoriasis	0.000378	0.00602	CbGpPWpGaD
Mitoxantrone—TOP2A—Methyltestosterone—Prednisone—psoriasis	0.000362	0.222	CbGdCrCtD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—NFKBIA—psoriasis	0.00036	0.00573	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—STAT3—psoriasis	0.000359	0.00572	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—CP—psoriasis	0.000354	0.00564	CbGpPWpGaD
Mitoxantrone—TOP2A—Methyltestosterone—Prednisolone—psoriasis	0.000353	0.217	CbGdCrCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—NFKBIA—psoriasis	0.000351	0.00559	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KIR2DS1—psoriasis	0.00035	0.00558	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000338	0.00538	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.000337	0.00537	CbGpPWpGaD
Mitoxantrone—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000337	0.00537	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.000336	0.00535	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000325	0.00517	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—JUN—psoriasis	0.000313	0.00498	CbGpPWpGaD
Mitoxantrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000313	0.00498	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—NFKBIA—psoriasis	0.000311	0.00495	CbGpPWpGaD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00031	0.00493	CbGpPWpGaD
Mitoxantrone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000309	0.00491	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—NFKB1—psoriasis	0.000301	0.0048	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—STAT3—psoriasis	0.0003	0.00477	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000296	0.00472	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—ERAP1—psoriasis	0.000296	0.00471	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—TYK2—psoriasis	0.000295	0.0047	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—NFKBIA—psoriasis	0.000292	0.00465	CbGpPWpGaD
Mitoxantrone—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.00029	0.00462	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000286	0.00456	CbGpPWpGaD
Mitoxantrone—TOP2A—Norethindrone—Hydrocortisone—psoriasis	0.000274	0.168	CbGdCrCtD
Mitoxantrone—BTK—Innate Immune System—DDX58—psoriasis	0.000271	0.00432	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HLA-B—psoriasis	0.000269	0.00429	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	0.000263	0.00419	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.00026	0.00414	CbGpPWpGaD
Mitoxantrone—CYP1B1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000256	0.00408	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—TYK2—psoriasis	0.000254	0.00405	CbGpPWpGaD
Mitoxantrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000253	0.00404	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—IL6—psoriasis	0.000251	0.004	CbGpPWpGaD
Mitoxantrone—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.00025	0.00399	CbGpPWpGaD
Mitoxantrone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00025	0.00398	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—psoriasis	0.000249	0.00396	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000241	0.00383	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—TYK2—psoriasis	0.000239	0.00381	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—JUN—psoriasis	0.000239	0.0038	CbGpPWpGaD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000233	0.00371	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—JUN—psoriasis	0.000233	0.00371	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	0.00023	0.00366	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—CP—psoriasis	0.000228	0.00363	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—NFKB1—psoriasis	0.000224	0.00357	CbGpPWpGaD
Mitoxantrone—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	0.000218	0.134	CbGdCrCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000218	0.00346	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	0.000217	0.00346	CbGpPWpGaD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000216	0.00344	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000213	0.00339	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000213	0.00339	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000208	0.00332	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—JUN—psoriasis	0.000206	0.00328	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000203	0.00323	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—NFKBIA—psoriasis	0.000201	0.0032	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—NFKB1—psoriasis	0.000198	0.00316	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—ITGAL—psoriasis	0.000197	0.00314	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	0.000194	0.00308	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000189	0.00301	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—TYK2—psoriasis	0.000189	0.00301	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	0.000188	0.00299	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000188	0.00299	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—IFIH1—psoriasis	0.000187	0.00297	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	0.000186	0.00297	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000186	0.00297	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000186	0.00296	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL13—psoriasis	0.000185	0.00294	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—REL—psoriasis	0.000185	0.00294	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000184	0.00293	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ERAP1—psoriasis	0.000179	0.00286	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	0.000178	0.00283	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—TYK2—psoriasis	0.000178	0.00283	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000177	0.00282	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HLA-C—psoriasis	0.000177	0.00282	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—TNFAIP3—psoriasis	0.000175	0.00278	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	0.000174	0.00278	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—JUN—psoriasis	0.000173	0.00275	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL17A—psoriasis	0.00017	0.00271	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HLA-C—psoriasis	0.00017	0.0027	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	0.000168	0.00268	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—PTTG1—psoriasis	0.000168	0.00267	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000166	0.00264	CbGpPWpGaD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000162	0.00259	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000161	0.00256	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000158	0.00252	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000158	0.00252	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—DDX58—psoriasis	0.000158	0.00251	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000154	0.00246	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HLA-E—psoriasis	0.000147	0.00234	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	0.000144	0.0023	CbGpPWpGaD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	0.000144	0.0023	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	0.000144	0.00229	CbGpPWpGaD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000144	0.00229	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HLA-E—psoriasis	0.000141	0.00224	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	0.000138	0.0022	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000138	0.00219	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000138	0.00219	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—LEP—psoriasis	0.000137	0.00218	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000135	0.00214	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000133	0.00211	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000133	0.00211	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	0.000131	0.00208	CbGpPWpGaD
Mitoxantrone—Constipation—Cyclosporine—psoriasis	0.000128	0.000443	CcSEcCtD
Mitoxantrone—Pain—Cyclosporine—psoriasis	0.000128	0.000443	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—NFKB1—psoriasis	0.000128	0.00204	CbGpPWpGaD
Mitoxantrone—Renal failure—Methotrexate—psoriasis	0.000128	0.000441	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000128	0.00203	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—NOS2—psoriasis	0.000127	0.00203	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000127	0.000439	CcSEcCtD
Mitoxantrone—Anorexia—Hydrocortisone—psoriasis	0.000127	0.000438	CcSEcCtD
Mitoxantrone—Diarrhoea—Mycophenolic acid—psoriasis	0.000127	0.000438	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—psoriasis	0.000127	0.000437	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—psoriasis	0.000126	0.000436	CcSEcCtD
Mitoxantrone—Malaise—Dexamethasone—psoriasis	0.000126	0.000434	CcSEcCtD
Mitoxantrone—Malaise—Betamethasone—psoriasis	0.000126	0.000434	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Triamcinolone—psoriasis	0.000125	0.000433	CcSEcCtD
Mitoxantrone—Oedema—Triamcinolone—psoriasis	0.000125	0.000433	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000125	0.002	CbGpPWpGaD
Mitoxantrone—Pain—Mycophenolate mofetil—psoriasis	0.000125	0.000432	CcSEcCtD
Mitoxantrone—Constipation—Mycophenolate mofetil—psoriasis	0.000125	0.000432	CcSEcCtD
Mitoxantrone—Arrhythmia—Prednisone—psoriasis	0.000125	0.00043	CcSEcCtD
Mitoxantrone—Infection—Triamcinolone—psoriasis	0.000125	0.00043	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—psoriasis	0.000125	0.00043	CcSEcCtD
Mitoxantrone—Hypotension—Hydrocortisone—psoriasis	0.000125	0.00043	CcSEcCtD
Mitoxantrone—BTK—Activated TLR4 signalling—IL6—psoriasis	0.000124	0.00198	CbGpPWpGaD
Mitoxantrone—Haematuria—Methotrexate—psoriasis	0.000124	0.000428	CcSEcCtD
Mitoxantrone—Feeling abnormal—Cyclosporine—psoriasis	0.000124	0.000427	CcSEcCtD
Mitoxantrone—Shock—Triamcinolone—psoriasis	0.000123	0.000426	CcSEcCtD
Mitoxantrone—Alopecia—Prednisone—psoriasis	0.000123	0.000426	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Cyclosporine—psoriasis	0.000123	0.000423	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—SOCS1—psoriasis	0.000123	0.00195	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Prednisolone—psoriasis	0.000123	0.000423	CcSEcCtD
Mitoxantrone—Tachycardia—Triamcinolone—psoriasis	0.000122	0.000423	CcSEcCtD
Mitoxantrone—Erythema—Prednisone—psoriasis	0.000121	0.000419	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000121	0.000419	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Triamcinolone—psoriasis	0.000121	0.000419	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—psoriasis	0.000121	0.000419	CcSEcCtD
Mitoxantrone—Convulsion—Dexamethasone—psoriasis	0.000121	0.000417	CcSEcCtD
Mitoxantrone—Convulsion—Betamethasone—psoriasis	0.000121	0.000417	CcSEcCtD
Mitoxantrone—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000121	0.000416	CcSEcCtD
Mitoxantrone—Hypertension—Dexamethasone—psoriasis	0.00012	0.000416	CcSEcCtD
Mitoxantrone—Hypertension—Betamethasone—psoriasis	0.00012	0.000416	CcSEcCtD
Mitoxantrone—Paraesthesia—Hydrocortisone—psoriasis	0.00012	0.000413	CcSEcCtD
Mitoxantrone—BTK—Immune System—ITGAL—psoriasis	0.00012	0.00191	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00012	0.000413	CcSEcCtD
Mitoxantrone—Urticaria—Cyclosporine—psoriasis	0.000119	0.000411	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—PPARG—psoriasis	0.000119	0.0019	CbGpPWpGaD
Mitoxantrone—Myalgia—Dexamethasone—psoriasis	0.000119	0.00041	CcSEcCtD
Mitoxantrone—Myalgia—Betamethasone—psoriasis	0.000119	0.00041	CcSEcCtD
Mitoxantrone—Abdominal pain—Cyclosporine—psoriasis	0.000119	0.000409	CcSEcCtD
Mitoxantrone—Body temperature increased—Cyclosporine—psoriasis	0.000119	0.000409	CcSEcCtD
Mitoxantrone—Anxiety—Dexamethasone—psoriasis	0.000118	0.000409	CcSEcCtD
Mitoxantrone—Anxiety—Betamethasone—psoriasis	0.000118	0.000409	CcSEcCtD
Mitoxantrone—Vomiting—Mycophenolic acid—psoriasis	0.000118	0.000407	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—SOCS1—psoriasis	0.000118	0.00187	CbGpPWpGaD
Mitoxantrone—Discomfort—Dexamethasone—psoriasis	0.000117	0.000405	CcSEcCtD
Mitoxantrone—Discomfort—Betamethasone—psoriasis	0.000117	0.000405	CcSEcCtD
Mitoxantrone—Dyspepsia—Hydrocortisone—psoriasis	0.000117	0.000405	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—psoriasis	0.000117	0.000405	CcSEcCtD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	0.000117	0.00186	CbGpPWpGaD
Mitoxantrone—Rash—Mycophenolic acid—psoriasis	0.000117	0.000403	CcSEcCtD
Mitoxantrone—Dermatitis—Mycophenolic acid—psoriasis	0.000117	0.000403	CcSEcCtD
Mitoxantrone—Pain—Prednisolone—psoriasis	0.000117	0.000403	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—psoriasis	0.000117	0.000403	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—psoriasis	0.000117	0.000403	CcSEcCtD
Mitoxantrone—Urticaria—Mycophenolate mofetil—psoriasis	0.000116	0.000401	CcSEcCtD
Mitoxantrone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000116	0.00185	CbGpPWpGaD
Mitoxantrone—Headache—Mycophenolic acid—psoriasis	0.000116	0.000401	CcSEcCtD
Mitoxantrone—Decreased appetite—Hydrocortisone—psoriasis	0.000116	0.0004	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—psoriasis	0.000116	0.0004	CcSEcCtD
Mitoxantrone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000116	0.000399	CcSEcCtD
Mitoxantrone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000116	0.000399	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—IL10—psoriasis	0.000115	0.00184	CbGpPWpGaD
Mitoxantrone—Fatigue—Hydrocortisone—psoriasis	0.000115	0.000397	CcSEcCtD
Mitoxantrone—Vision blurred—Prednisone—psoriasis	0.000114	0.000395	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000114	0.000395	CcSEcCtD
Mitoxantrone—Pain—Hydrocortisone—psoriasis	0.000114	0.000393	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Betamethasone—psoriasis	0.000114	0.000393	CcSEcCtD
Mitoxantrone—Oedema—Betamethasone—psoriasis	0.000114	0.000393	CcSEcCtD
Mitoxantrone—Oedema—Dexamethasone—psoriasis	0.000114	0.000393	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Dexamethasone—psoriasis	0.000114	0.000393	CcSEcCtD
Mitoxantrone—Infection—Dexamethasone—psoriasis	0.000113	0.00039	CcSEcCtD
Mitoxantrone—Infection—Betamethasone—psoriasis	0.000113	0.00039	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Prednisone—psoriasis	0.000113	0.000389	CcSEcCtD
Mitoxantrone—Paraesthesia—Triamcinolone—psoriasis	0.000113	0.000389	CcSEcCtD
Mitoxantrone—Feeling abnormal—Prednisolone—psoriasis	0.000112	0.000388	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—IL4—psoriasis	0.000112	0.00179	CbGpPWpGaD
Mitoxantrone—Anaemia—Prednisone—psoriasis	0.000112	0.000388	CcSEcCtD
Mitoxantrone—Shock—Betamethasone—psoriasis	0.000112	0.000387	CcSEcCtD
Mitoxantrone—Shock—Dexamethasone—psoriasis	0.000112	0.000387	CcSEcCtD
Mitoxantrone—BTK—Immune System—REL—psoriasis	0.000112	0.00178	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Triamcinolone—psoriasis	0.000112	0.000386	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Betamethasone—psoriasis	0.000111	0.000385	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Dexamethasone—psoriasis	0.000111	0.000385	CcSEcCtD
Mitoxantrone—Tachycardia—Betamethasone—psoriasis	0.000111	0.000384	CcSEcCtD
Mitoxantrone—Tachycardia—Dexamethasone—psoriasis	0.000111	0.000384	CcSEcCtD
Mitoxantrone—Hypersensitivity—Cyclosporine—psoriasis	0.00011	0.000381	CcSEcCtD
Mitoxantrone—Dyspepsia—Triamcinolone—psoriasis	0.00011	0.000381	CcSEcCtD
Mitoxantrone—Nausea—Mycophenolic acid—psoriasis	0.00011	0.00038	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Betamethasone—psoriasis	0.00011	0.00038	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Dexamethasone—psoriasis	0.00011	0.00038	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-B—psoriasis	0.00011	0.00175	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Hydrocortisone—psoriasis	0.00011	0.000379	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.00011	0.00175	CbGpPWpGaD
Mitoxantrone—Malaise—Prednisone—psoriasis	0.00011	0.000378	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.00011	0.00174	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000109	0.000376	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000109	0.00174	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IFIH1—psoriasis	0.000109	0.00173	CbGpPWpGaD
Mitoxantrone—Anorexia—Dexamethasone—psoriasis	0.000109	0.000375	CcSEcCtD
Mitoxantrone—Anorexia—Betamethasone—psoriasis	0.000109	0.000375	CcSEcCtD
Mitoxantrone—Urticaria—Prednisolone—psoriasis	0.000108	0.000374	CcSEcCtD
Mitoxantrone—Fatigue—Triamcinolone—psoriasis	0.000108	0.000373	CcSEcCtD
Mitoxantrone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000108	0.000372	CcSEcCtD
Mitoxantrone—Asthenia—Cyclosporine—psoriasis	0.000108	0.000371	CcSEcCtD
Mitoxantrone—Pain—Triamcinolone—psoriasis	0.000107	0.00037	CcSEcCtD
Mitoxantrone—Hypotension—Dexamethasone—psoriasis	0.000106	0.000367	CcSEcCtD
Mitoxantrone—Hypotension—Betamethasone—psoriasis	0.000106	0.000367	CcSEcCtD
Mitoxantrone—Urticaria—Hydrocortisone—psoriasis	0.000106	0.000365	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	0.000105	0.00168	CbGpPWpGaD
Mitoxantrone—Abdominal pain—Hydrocortisone—psoriasis	0.000105	0.000364	CcSEcCtD
Mitoxantrone—Body temperature increased—Hydrocortisone—psoriasis	0.000105	0.000364	CcSEcCtD
Mitoxantrone—Convulsion—Prednisone—psoriasis	0.000105	0.000363	CcSEcCtD
Mitoxantrone—Asthenia—Mycophenolate mofetil—psoriasis	0.000105	0.000362	CcSEcCtD
Mitoxantrone—Hypertension—Prednisone—psoriasis	0.000105	0.000362	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—psoriasis	0.000105	0.000361	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—HLA-B—psoriasis	0.000105	0.00167	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD8A—psoriasis	0.000104	0.00166	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—IL6—psoriasis	0.000104	0.00166	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000104	0.000358	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000104	0.000358	CcSEcCtD
Mitoxantrone—Myalgia—Prednisone—psoriasis	0.000103	0.000357	CcSEcCtD
Mitoxantrone—Arthralgia—Prednisone—psoriasis	0.000103	0.000357	CcSEcCtD
Mitoxantrone—Feeling abnormal—Triamcinolone—psoriasis	0.000103	0.000357	CcSEcCtD
Mitoxantrone—Anxiety—Prednisone—psoriasis	0.000103	0.000356	CcSEcCtD
Mitoxantrone—Alopecia—Methotrexate—psoriasis	0.000103	0.000356	CcSEcCtD
Mitoxantrone—BTK—Immune System—HLA-C—psoriasis	0.000103	0.00164	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Cyclosporine—psoriasis	0.000103	0.000354	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000102	0.00163	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Betamethasone—psoriasis	0.000102	0.000353	CcSEcCtD
Mitoxantrone—Paraesthesia—Dexamethasone—psoriasis	0.000102	0.000353	CcSEcCtD
Mitoxantrone—Discomfort—Prednisone—psoriasis	0.000102	0.000353	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-A—psoriasis	0.000102	0.00162	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—TNFAIP3—psoriasis	0.000102	0.00162	CbGpPWpGaD
Mitoxantrone—Erythema—Methotrexate—psoriasis	0.000102	0.00035	CcSEcCtD
Mitoxantrone—Hypersensitivity—Prednisolone—psoriasis	0.000101	0.000347	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—HLA-B—psoriasis	0.0001	0.0016	CbGpPWpGaD
Mitoxantrone—Dyspepsia—Dexamethasone—psoriasis	0.0001	0.000346	CcSEcCtD
Mitoxantrone—Dyspepsia—Betamethasone—psoriasis	0.0001	0.000346	CcSEcCtD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.0001	0.00159	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.0001	0.000345	CcSEcCtD
Mitoxantrone—Urticaria—Triamcinolone—psoriasis	9.97e-05	0.000344	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—psoriasis	9.94e-05	0.000343	CcSEcCtD
Mitoxantrone—Body temperature increased—Triamcinolone—psoriasis	9.92e-05	0.000342	CcSEcCtD
Mitoxantrone—Oedema—Prednisone—psoriasis	9.91e-05	0.000342	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Prednisone—psoriasis	9.91e-05	0.000342	CcSEcCtD
Mitoxantrone—Decreased appetite—Dexamethasone—psoriasis	9.9e-05	0.000342	CcSEcCtD
Mitoxantrone—Decreased appetite—Betamethasone—psoriasis	9.9e-05	0.000342	CcSEcCtD
Mitoxantrone—Infection—Prednisone—psoriasis	9.85e-05	0.00034	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—psoriasis	9.82e-05	0.000339	CcSEcCtD
Mitoxantrone—Hypersensitivity—Hydrocortisone—psoriasis	9.82e-05	0.000339	CcSEcCtD
Mitoxantrone—Fatigue—Dexamethasone—psoriasis	9.82e-05	0.000339	CcSEcCtD
Mitoxantrone—Fatigue—Betamethasone—psoriasis	9.82e-05	0.000339	CcSEcCtD
Mitoxantrone—Shock—Prednisone—psoriasis	9.75e-05	0.000337	CcSEcCtD
Mitoxantrone—Pain—Betamethasone—psoriasis	9.74e-05	0.000336	CcSEcCtD
Mitoxantrone—Pain—Dexamethasone—psoriasis	9.74e-05	0.000336	CcSEcCtD
Mitoxantrone—Tachycardia—Prednisone—psoriasis	9.68e-05	0.000334	CcSEcCtD
Mitoxantrone—Skin disorder—Prednisone—psoriasis	9.63e-05	0.000332	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Prednisone—psoriasis	9.58e-05	0.000331	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—psoriasis	9.57e-05	0.00033	CcSEcCtD
Mitoxantrone—Asthenia—Hydrocortisone—psoriasis	9.56e-05	0.00033	CcSEcCtD
Mitoxantrone—Vomiting—Cyclosporine—psoriasis	9.53e-05	0.000329	CcSEcCtD
Mitoxantrone—Rash—Cyclosporine—psoriasis	9.45e-05	0.000326	CcSEcCtD
Mitoxantrone—Anorexia—Prednisone—psoriasis	9.45e-05	0.000326	CcSEcCtD
Mitoxantrone—Dermatitis—Cyclosporine—psoriasis	9.45e-05	0.000326	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Methotrexate—psoriasis	9.42e-05	0.000325	CcSEcCtD
Mitoxantrone—Headache—Cyclosporine—psoriasis	9.39e-05	0.000324	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—psoriasis	9.38e-05	0.000324	CcSEcCtD
Mitoxantrone—Feeling abnormal—Betamethasone—psoriasis	9.38e-05	0.000324	CcSEcCtD
Mitoxantrone—Feeling abnormal—Dexamethasone—psoriasis	9.38e-05	0.000324	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Dexamethasone—psoriasis	9.31e-05	0.000321	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Betamethasone—psoriasis	9.31e-05	0.000321	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—HLA-A—psoriasis	9.3e-05	0.00148	CbGpPWpGaD
Mitoxantrone—Vomiting—Mycophenolate mofetil—psoriasis	9.3e-05	0.000321	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	9.3e-05	0.00148	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Triamcinolone—psoriasis	9.24e-05	0.000319	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—CRP—psoriasis	9.24e-05	0.00147	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NDUFA5—psoriasis	9.24e-05	0.00147	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—IL6—psoriasis	9.24e-05	0.00147	CbGpPWpGaD
Mitoxantrone—Rash—Mycophenolate mofetil—psoriasis	9.22e-05	0.000318	CcSEcCtD
Mitoxantrone—Dermatitis—Mycophenolate mofetil—psoriasis	9.21e-05	0.000318	CcSEcCtD
Mitoxantrone—Headache—Mycophenolate mofetil—psoriasis	9.16e-05	0.000316	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—psoriasis	9.16e-05	0.000316	CcSEcCtD
Mitoxantrone—Diarrhoea—Hydrocortisone—psoriasis	9.12e-05	0.000315	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—psoriasis	9.09e-05	0.000314	CcSEcCtD
Mitoxantrone—Urticaria—Dexamethasone—psoriasis	9.04e-05	0.000312	CcSEcCtD
Mitoxantrone—Urticaria—Betamethasone—psoriasis	9.04e-05	0.000312	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Prednisone—psoriasis	9.03e-05	0.000312	CcSEcCtD
Mitoxantrone—Asthenia—Triamcinolone—psoriasis	9e-05	0.000311	CcSEcCtD
Mitoxantrone—Abdominal pain—Dexamethasone—psoriasis	9e-05	0.000311	CcSEcCtD
Mitoxantrone—Body temperature increased—Betamethasone—psoriasis	9e-05	0.000311	CcSEcCtD
Mitoxantrone—Abdominal pain—Betamethasone—psoriasis	9e-05	0.000311	CcSEcCtD
Mitoxantrone—Body temperature increased—Dexamethasone—psoriasis	9e-05	0.000311	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—NDUFA5—psoriasis	8.93e-05	0.00142	CbGpPWpGaD
Mitoxantrone—Nausea—Cyclosporine—psoriasis	8.91e-05	0.000307	CcSEcCtD
Mitoxantrone—Paraesthesia—Prednisone—psoriasis	8.9e-05	0.000307	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—psoriasis	8.86e-05	0.000306	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.8e-05	0.0014	CbGpPWpGaD
Mitoxantrone—Convulsion—Methotrexate—psoriasis	8.8e-05	0.000304	CcSEcCtD
Mitoxantrone—Dyspepsia—Prednisone—psoriasis	8.73e-05	0.000301	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—IL6—psoriasis	8.69e-05	0.00138	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	8.69e-05	0.00138	CbGpPWpGaD
Mitoxantrone—Nausea—Mycophenolate mofetil—psoriasis	8.69e-05	0.0003	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—psoriasis	8.64e-05	0.000298	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—psoriasis	8.64e-05	0.000298	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—psoriasis	8.64e-05	0.000298	CcSEcCtD
Mitoxantrone—Decreased appetite—Prednisone—psoriasis	8.62e-05	0.000298	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.61e-05	0.00137	CbGpPWpGaD
Mitoxantrone—Rash—Prednisolone—psoriasis	8.6e-05	0.000297	CcSEcCtD
Mitoxantrone—Dermatitis—Prednisolone—psoriasis	8.59e-05	0.000297	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	8.58e-05	0.00137	CbGpPWpGaD
Mitoxantrone—Fatigue—Prednisone—psoriasis	8.55e-05	0.000295	CcSEcCtD
Mitoxantrone—Headache—Prednisolone—psoriasis	8.55e-05	0.000295	CcSEcCtD
Mitoxantrone—BTK—Immune System—HLA-E—psoriasis	8.55e-05	0.00136	CbGpPWpGaD
Mitoxantrone—Discomfort—Methotrexate—psoriasis	8.54e-05	0.000295	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—HLA-DRB1—psoriasis	8.5e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Constipation—Prednisone—psoriasis	8.48e-05	0.000293	CcSEcCtD
Mitoxantrone—Vomiting—Hydrocortisone—psoriasis	8.47e-05	0.000292	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.47e-05	0.00135	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—JUN—psoriasis	8.45e-05	0.00135	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NFKBIA—psoriasis	8.43e-05	0.00134	CbGpPWpGaD
Mitoxantrone—Rash—Hydrocortisone—psoriasis	8.4e-05	0.00029	CcSEcCtD
Mitoxantrone—Dermatitis—Hydrocortisone—psoriasis	8.39e-05	0.00029	CcSEcCtD
Mitoxantrone—Confusional state—Methotrexate—psoriasis	8.35e-05	0.000288	CcSEcCtD
Mitoxantrone—Headache—Hydrocortisone—psoriasis	8.35e-05	0.000288	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.33e-05	0.00133	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Methotrexate—psoriasis	8.29e-05	0.000286	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—psoriasis	8.23e-05	0.000284	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	8.19e-05	0.0013	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Prednisone—psoriasis	8.17e-05	0.000282	CcSEcCtD
Mitoxantrone—Asthenia—Dexamethasone—psoriasis	8.17e-05	0.000282	CcSEcCtD
Mitoxantrone—Asthenia—Betamethasone—psoriasis	8.17e-05	0.000282	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—ICAM1—psoriasis	8.16e-05	0.0013	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NDUFA5—psoriasis	8.13e-05	0.00129	CbGpPWpGaD
Mitoxantrone—Thrombocytopenia—Methotrexate—psoriasis	8.11e-05	0.00028	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Prednisone—psoriasis	8.11e-05	0.00028	CcSEcCtD
Mitoxantrone—Nausea—Prednisolone—psoriasis	8.1e-05	0.00028	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—NFKBIA—psoriasis	8.09e-05	0.00129	CbGpPWpGaD
Mitoxantrone—Skin disorder—Methotrexate—psoriasis	8.05e-05	0.000278	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—psoriasis	8.01e-05	0.000277	CcSEcCtD
Mitoxantrone—Vomiting—Triamcinolone—psoriasis	7.98e-05	0.000275	CcSEcCtD
Mitoxantrone—Nausea—Hydrocortisone—psoriasis	7.92e-05	0.000273	CcSEcCtD
Mitoxantrone—Rash—Triamcinolone—psoriasis	7.91e-05	0.000273	CcSEcCtD
Mitoxantrone—Dermatitis—Triamcinolone—psoriasis	7.9e-05	0.000273	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—psoriasis	7.9e-05	0.000273	CcSEcCtD
Mitoxantrone—Urticaria—Prednisone—psoriasis	7.88e-05	0.000272	CcSEcCtD
Mitoxantrone—Headache—Triamcinolone—psoriasis	7.86e-05	0.000271	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—CYP2S1—psoriasis	7.85e-05	0.00125	CbGpPWpGaD
Mitoxantrone—Abdominal pain—Prednisone—psoriasis	7.84e-05	0.000271	CcSEcCtD
Mitoxantrone—Body temperature increased—Prednisone—psoriasis	7.84e-05	0.000271	CcSEcCtD
Mitoxantrone—Diarrhoea—Dexamethasone—psoriasis	7.79e-05	0.000269	CcSEcCtD
Mitoxantrone—Diarrhoea—Betamethasone—psoriasis	7.79e-05	0.000269	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—psoriasis	7.74e-05	0.000267	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.69e-05	0.00122	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	7.65e-05	0.00122	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CYP2S1—psoriasis	7.6e-05	0.00121	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	7.55e-05	0.0012	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—psoriasis	7.55e-05	0.000261	CcSEcCtD
Mitoxantrone—Nausea—Triamcinolone—psoriasis	7.45e-05	0.000257	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—psoriasis	7.44e-05	0.000257	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—psoriasis	7.39e-05	0.000255	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—psoriasis	7.37e-05	0.000254	CcSEcCtD
Mitoxantrone—Hypersensitivity—Prednisone—psoriasis	7.3e-05	0.000252	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—psoriasis	7.29e-05	0.000252	CcSEcCtD
Mitoxantrone—Vomiting—Dexamethasone—psoriasis	7.24e-05	0.00025	CcSEcCtD
Mitoxantrone—Vomiting—Betamethasone—psoriasis	7.24e-05	0.00025	CcSEcCtD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	7.21e-05	0.00115	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Methotrexate—psoriasis	7.2e-05	0.000249	CcSEcCtD
Mitoxantrone—Rash—Dexamethasone—psoriasis	7.18e-05	0.000248	CcSEcCtD
Mitoxantrone—Rash—Betamethasone—psoriasis	7.18e-05	0.000248	CcSEcCtD
Mitoxantrone—Dermatitis—Betamethasone—psoriasis	7.17e-05	0.000248	CcSEcCtD
Mitoxantrone—Dermatitis—Dexamethasone—psoriasis	7.17e-05	0.000248	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—psoriasis	7.14e-05	0.000247	CcSEcCtD
Mitoxantrone—BTK—Immune System—SOCS1—psoriasis	7.14e-05	0.00114	CbGpPWpGaD
Mitoxantrone—Headache—Betamethasone—psoriasis	7.13e-05	0.000246	CcSEcCtD
Mitoxantrone—Headache—Dexamethasone—psoriasis	7.13e-05	0.000246	CcSEcCtD
Mitoxantrone—Asthenia—Prednisone—psoriasis	7.11e-05	0.000246	CcSEcCtD
Mitoxantrone—Pain—Methotrexate—psoriasis	7.09e-05	0.000245	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—CYP2S1—psoriasis	6.91e-05	0.0011	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—TYK2—psoriasis	6.9e-05	0.0011	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—PCNA—psoriasis	6.84e-05	0.00109	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Methotrexate—psoriasis	6.83e-05	0.000236	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—IFNG—psoriasis	6.79e-05	0.00108	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Prednisone—psoriasis	6.78e-05	0.000234	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	6.78e-05	0.00108	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Methotrexate—psoriasis	6.78e-05	0.000234	CcSEcCtD
Mitoxantrone—Nausea—Dexamethasone—psoriasis	6.76e-05	0.000233	CcSEcCtD
Mitoxantrone—Nausea—Betamethasone—psoriasis	6.76e-05	0.000233	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.59e-05	0.00105	CbGpPWpGaD
Mitoxantrone—Urticaria—Methotrexate—psoriasis	6.58e-05	0.000227	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—psoriasis	6.55e-05	0.000226	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—psoriasis	6.55e-05	0.000226	CcSEcCtD
Mitoxantrone—BTK—Immune System—CD8A—psoriasis	6.33e-05	0.00101	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—CXCL8—psoriasis	6.32e-05	0.00101	CbGpPWpGaD
Mitoxantrone—Vomiting—Prednisone—psoriasis	6.3e-05	0.000218	CcSEcCtD
Mitoxantrone—Rash—Prednisone—psoriasis	6.25e-05	0.000216	CcSEcCtD
Mitoxantrone—Dermatitis—Prednisone—psoriasis	6.25e-05	0.000216	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—CD4—psoriasis	6.24e-05	0.000994	CbGpPWpGaD
Mitoxantrone—Headache—Prednisone—psoriasis	6.21e-05	0.000214	CcSEcCtD
Mitoxantrone—Hypersensitivity—Methotrexate—psoriasis	6.1e-05	0.000211	CcSEcCtD
Mitoxantrone—BTK—Immune System—HLA-B—psoriasis	6.09e-05	0.00097	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD4—psoriasis	6e-05	0.000955	CbGpPWpGaD
Mitoxantrone—Asthenia—Methotrexate—psoriasis	5.94e-05	0.000205	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.92e-05	0.000943	CbGpPWpGaD
Mitoxantrone—Nausea—Prednisone—psoriasis	5.89e-05	0.000203	CcSEcCtD
Mitoxantrone—CYP2E1—Metabolism—NDUFA5—psoriasis	5.84e-05	0.00093	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.81e-05	0.000925	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Methotrexate—psoriasis	5.67e-05	0.000196	CcSEcCtD
Mitoxantrone—BTK—Immune System—HLA-A—psoriasis	5.64e-05	0.000899	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—JUN—psoriasis	5.59e-05	0.00089	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—psoriasis	5.58e-05	0.000888	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CRP—psoriasis	5.38e-05	0.000857	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NFKB1—psoriasis	5.38e-05	0.000857	CbGpPWpGaD
Mitoxantrone—Vomiting—Methotrexate—psoriasis	5.27e-05	0.000182	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—psoriasis	5.22e-05	0.00018	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—psoriasis	5.22e-05	0.00018	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.2e-05	0.000828	CbGpPWpGaD
Mitoxantrone—Headache—Methotrexate—psoriasis	5.19e-05	0.000179	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—NFKB1—psoriasis	5.17e-05	0.000823	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HLA-DRB1—psoriasis	5.16e-05	0.000821	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—VEGFA—psoriasis	5.13e-05	0.000817	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—IL6—psoriasis	5.1e-05	0.000813	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CYP2S1—psoriasis	4.96e-05	0.00079	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ICAM1—psoriasis	4.95e-05	0.000788	CbGpPWpGaD
Mitoxantrone—Nausea—Methotrexate—psoriasis	4.92e-05	0.00017	CcSEcCtD
Mitoxantrone—BTK—Immune System—NFKBIA—psoriasis	4.91e-05	0.000782	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TNF—psoriasis	4.4e-05	0.0007	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NDUFA5—psoriasis	4.39e-05	0.0007	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.37e-05	0.000696	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.12e-05	0.000656	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	4.08e-05	0.000651	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—TYK2—psoriasis	4.02e-05	0.00064	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.98e-05	0.000634	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.9e-05	0.000621	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CARM1—psoriasis	3.84e-05	0.000611	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IFNG—psoriasis	3.77e-05	0.0006	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CYP2S1—psoriasis	3.74e-05	0.000595	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CARM1—psoriasis	3.71e-05	0.000591	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD4—psoriasis	3.64e-05	0.000579	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.59e-05	0.000571	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.47e-05	0.000552	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—IL6—psoriasis	3.38e-05	0.000538	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CARM1—psoriasis	3.38e-05	0.000538	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—JUN—psoriasis	3.25e-05	0.000518	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—NFKB1—psoriasis	3.13e-05	0.000499	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.9e-05	0.000461	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—STAT3—psoriasis	2.82e-05	0.000448	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.79e-05	0.000444	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NDUFA5—psoriasis	2.71e-05	0.000431	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.53e-05	0.000403	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—psoriasis	2.51e-05	0.0004	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CARM1—psoriasis	2.42e-05	0.000386	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CAT—psoriasis	2.36e-05	0.000376	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HLA-A—psoriasis	2.34e-05	0.000373	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CYP2S1—psoriasis	2.3e-05	0.000367	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CAT—psoriasis	2.28e-05	0.000363	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—APOE—psoriasis	2.19e-05	0.000349	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.17e-05	0.000346	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CAT—psoriasis	2.08e-05	0.000331	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NOS2—psoriasis	2.04e-05	0.000325	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL6—psoriasis	1.97e-05	0.000313	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.91e-05	0.000305	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—APOE—psoriasis	1.83e-05	0.000292	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CARM1—psoriasis	1.82e-05	0.000291	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—APOE—psoriasis	1.77e-05	0.000282	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TYK2—psoriasis	1.67e-05	0.000266	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—APOE—psoriasis	1.61e-05	0.000257	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PPARG—psoriasis	1.6e-05	0.000254	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PPARG—psoriasis	1.54e-05	0.000246	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CD4—psoriasis	1.51e-05	0.000241	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CAT—psoriasis	1.49e-05	0.000237	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PPARG—psoriasis	1.41e-05	0.000224	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—STAT3—psoriasis	1.17e-05	0.000186	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—APOE—psoriasis	1.16e-05	0.000184	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CARM1—psoriasis	1.12e-05	0.000179	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CAT—psoriasis	1.12e-05	0.000179	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PPARG—psoriasis	1.01e-05	0.000161	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—APOE—psoriasis	8.72e-06	0.000139	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—IL6—psoriasis	8.17e-06	0.00013	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PPARG—psoriasis	7.6e-06	0.000121	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CAT—psoriasis	6.92e-06	0.00011	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—APOE—psoriasis	5.37e-06	8.56e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PPARG—psoriasis	4.68e-06	7.45e-05	CbGpPWpGaD
